AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Tom Lee, Fundstrat Global Advisors managing partner and head of research, appeared on CNBC to talk about his 2025 playbook.

This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

AbbVie stock trades at a forward price-to-earnings (P/E) ratio of 14.2, representing a significant discount to the S&P 500's ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...